Embera NeuroTherapeutics says it has garnered $4.5 million in a continuation of its Series A financing. The money will go to development of new treatments for smoking cessation and other addictions. "This investment will enable us to complete preclinical development for EMB-001 and to bring this drug candidate entirely through a Phase I safety study," said CEO Bob Linke. Release